AbbVie Inc. (ABBV)

68.54
NYSE : Health Technology
Prev Close 68.25
Day Low/High 68.10 / 68.82
52 Wk Low/High 65.06 / 100.23
Avg Volume 8.81M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 100.90B
EPS 3.70
P/E Ratio 19.06
Div & Yield 4.28 (5.94%)
5 Healthy Pharma and Biotech Plays

5 Healthy Pharma and Biotech Plays

These stocks look good as seasonal volatility sets in.

Dive Safely Into These 12 Dividend Payers

Dive Safely Into These 12 Dividend Payers

If and when interest rates go up, this basket of stocks should continue to do well.

Abbvie downgraded at JP Morgan

Cramer: The Answer to This Market: Part 1

Cramer: The Answer to This Market: Part 1

The leadership is quite stark.

TG Therapeutics Looks Like a Healthy Play

TG Therapeutics Looks Like a Healthy Play

Small biotech tanked on weak earnings, but still seems promising.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Closing Bell: AbbVie Sues Amgen; S&P 500, Nasdaq at New Records

Stocks secure robust gains after the latest labor market snapshot breezes past expectations.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

Portfolio Roundup: Humira Helps Buoy AbbVie Shares

The drug maker continued to rally Monday.

Grasping for Growth in a Broken Economy

Grasping for Growth in a Broken Economy

The bifurcation can be seen just by looking at Apple's recent results.

AbbVie Shares Rise on Revenue Jump

AbbVie Shares Rise on Revenue Jump

Shares of AbbVie were up Friday after the company reported a big jump in revenue.

AbbVie Is Still Pointed Up, for Now

AbbVie Is Still Pointed Up, for Now

Consider raising your sell stop protection to a close below $61.

Trending Tickers: BUD, ABBV, SRCL, EXPE

Trending Tickers: BUD, ABBV, SRCL, EXPE

The Anheuser-Busch InBev and SABMiller deal is another step closer to completion.

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

Take Stock of Your High-Dividend Stocks

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

8 Beaten-Down Post-Brexit Bargains

8 Beaten-Down Post-Brexit Bargains

These names are now oversold and are sitting at attractive prices.

Infinity Pharmaceuticals Cannot Cure Downgrades After Drug Study

Analysts cut valuation estimates after a disappointing drug study. 

Why Adding AbbVie Is the Pill to Take

Why Adding AbbVie Is the Pill to Take

With the recent pullback in the stock price, AbbVie is an attractive buy.  

Tweets on the Street: Investing in Fitness Innovation; Market Volatility Spikes

Social media chatter on Wall Street ranged from new forms of so-called 'thematic ETFs' to spiking volatility.

Abbvie downgraded at BMO

AbbVie Gears Up for an Even Higher Run

Further near-term weakness to $60 looks like a good spot to go long. Use an appropriate risk level.

Cramer: Many Portfolio Managers Hope for the 'Wrong' Jobs Number

This is because they would buy more of the winning stocks lower.

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

3 Small Biotechs Make Some Noise on a Quiet Day

The market is having a quiet day in front of the long holiday weekend. However, biotech is concluding another strong week, which makes two in a row. I'm noticing some small biotechs on the move today. Aratana Therapeutics (PETX) is up 7% today. Ther...

Remain Patient in This Sideways Market

Remain Patient in This Sideways Market

Keep cash on hand and be ready for oportunities as they arise.

2 Big -- and Mispriced -- Biotech Stocks

2 Big -- and Mispriced -- Biotech Stocks

AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.

2 Portfolios for the Fundamentally Sound

2 Portfolios for the Fundamentally Sound

We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.

Trending Tickers: HD, P, ABBV, ODP, LC

Home Depot shares were falling despite a strong first-quarter showing. 

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.